Subdermal implantation of the collagen-elastin-matrix Matriderm® to improve profile and skin structure of degenerative changes in the midface region [Subkutaner einsatz der kollagen-elastin-matrix Matriderm® zur verbesserung von profil und hautstruktur bei degenerativen veränderungen des mittelgesichtes]

Submission date	Recruitment status	Prospectively registered
15/05/2009	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
31/07/2009	Completed	Results
Last Edited	Condition category	Individual participant data
31/07/2009	Skin and Connective Tissue Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Henrik Menke

Contact details

Klinik für Plastische-, Ästhetische- und Handchirurgie Schwerbrandverletztenzentrum Starkenburgring 66 Offenbach Germany 63069

Additional identifiers

Protocol serial number

DE/CA22/2-2008/KLP

Study information

Scientific Title

Subdermal implantation of the collagen-elastin-matrix Matriderm® to improve profile and skin structure of degenerative changes in the midface region: a non-randomised single arm clinical trial

Acronym

SIMAMID II

Study objectives

Collagen matrices are in clinical use in plastic and burn surgery under split skin for dermal regeneration; in this study we investigate the effects of subdermal implantation of the matrix under healthy skin on mid-face profile, skin quality and dermal architecture.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The local ethics committee (Ethik-Kommission bei der Landesärztekammer Hessen) approved on the 4th June 2008 (ref: FF 29/2008)

Study design

Non-randomised single-arm clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Degenerative structure of profile and/or skin quality in the mid-face, caused by disease or ageing

Interventions

Step 1: Subdermal laminar implantation of a collagen-elastin-matrix on the upper arm Step 2: Subdermal laminar implantation of a collagen-elastin-matrix on the mid-face region

Skin biopsies (upper arm) before, 6 and 12 months post-operatively.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Matriderm®

Primary outcome(s)

Clinical outcome of mid-face region, measured at month 8 after step 1 (upper arm).

Key secondary outcome(s))

Clinical, histological and cutometric outcome upper arm, measured at month 14 after step 1 (upper arm).

Completion date

14/11/2009

Eligibility

Key inclusion criteria

Healthy adults aged 40 - 65 years, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Αll

Key exclusion criteria

- 1. Severe allergies
- 2. Severe acute or chronic diseases
- 3. Skin infections

Date of first enrolment

15/05/2008

Date of final enrolment

14/11/2009

Locations

Countries of recruitment

Germany

Study participating centre Klinik für Plastische-, Ästhetische- und Handchirurgie

Offenbach

Sponsor information

Organisation

Dr Suwelack Skin and Health Care AG (Germany)

ROR

https://ror.org/05hqyp882

Funder(s)

Funder type

Industry

Funder Name

Dr Suwelack Skin and Health Care AG (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes